Voquezna is a drug owned by Phathom Pharmaceuticals Inc. It is protected by 2 US drug patents filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 11, 2030. Details of Voquezna's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | |||
| US7977488 | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors |
Aug, 2028
(4 years from now) | Active |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9186411 | Pharmaceutical composition |
Aug, 2030
(6 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Voquezna's patents.
Latest Legal Activities on Voquezna's Patents
Given below is the list of recent legal activities going on the following patents of Voquezna.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Second letter to regulating agency to determine regulatory review period | 01 Mar, 2024 | US7977488 |
| Letter from FDA or Dept of Agriculture re PTE application | 24 Jan, 2024 | US7977488 |
| Initial letter Re: PTE Application to regulating agency | 17 Aug, 2023 | US7977488 |
| Change in Power of Attorney (May Include Associate POA) | 16 Jun, 2023 | US9186411 |
| Email Notification | 16 Jun, 2023 | US9186411 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Apr, 2023 | US9186411 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Dec, 2022 | US7977488 |
| Change in Power of Attorney (May Include Associate POA) | 13 Jul, 2022 | US7977488 |
| Email Notification | 13 Jul, 2022 | US7977488 |
| Correspondence Address Change | 12 Jul, 2022 | US7977488 |
FDA has granted several exclusivities to Voquezna. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Voquezna, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Voquezna.
Exclusivity Information
Voquezna holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2027. Details of Voquezna's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 01, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 03, 2027 |
US patents provide insights into the exclusivity only within the United States, but Voquezna is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Voquezna's family patents as well as insights into ongoing legal events on those patents.
Voquezna's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Voquezna's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 11, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Voquezna Generics:
There are no approved generic versions for Voquezna as of now.
About Voquezna
Voquezna is a drug owned by Phathom Pharmaceuticals Inc. Voquezna uses Vonoprazan Fumarate as an active ingredient. Voquezna was launched by Phathom in 2023.
Market Authorisation Date:
Voquezna was approved by FDA for market use on 01 November, 2023.
NCE-1 date:
NCE-1 date is also known as the four year date as it is four years after the original drug approval. Since the approval date for Voquezna is 01 November, 2023, its NCE-1 date is estimated to be 03 May, 2026
Active Ingredient:
Voquezna uses Vonoprazan Fumarate as the active ingredient. Check out other Drugs and Companies using Vonoprazan Fumarate ingredient
Dosage:
Voquezna is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 20MG BASE | TABLET | Prescription | ORAL |
| EQ 10MG BASE | TABLET | Prescription | ORAL |